Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Kathryn Canavan

Advertisement

Articles by Kathryn Canavan

Survivorship Care Plans: Should Every Patient Have One?

ByKathryn Canavan
October 28th 2011

The number of cancer survivors in the United States has quadrupled since 1971, making it imperative for healthcare professionals to identify and address the needs of this burgeoning population.

Advertisement

Latest Updated Articles

  • Survivorship Care Plans: Should Every Patient Have One?
    Survivorship Care Plans: Should Every Patient Have One?

    October 28th 2011



Advertisement
Advertisement

Trending on OncLive

1

FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer

2

FDA Grants Orphan Drug Designation to Zocilurtatug Pelitecan for Neuroendocrine Carcinomas

3

Sapablursen Represents Potential Avenue for Improved Hepcidin Production in Polycythemia Vera

4

Dr Cohen on FcRH5 as a Therapeutic Target in Multiple Myeloma

5

Mayo Clinic–Led Study Finds No Improvement in Overall Survival From Longer Multiple Myeloma Maintenance Therapy

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us